A detailed history of New Edge Advisors, LLC transactions in Sarepta Therapeutics, Inc. stock. As of the latest transaction made, New Edge Advisors, LLC holds 8,930 shares of SRPT stock, worth $1.02 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares
8,930
Previous 5,591 59.72%
Holding current value
$1.02 Million
Previous $883,000 26.27%
% of portfolio
0.01%
Previous 0.01%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$124.33 - $156.75 $415,137 - $523,388
3,339 Added 59.72%
8,930 $1.12 Million
Q2 2024

Aug 15, 2024

SELL
$113.33 - $163.85 $154,468 - $223,327
-1,363 Reduced 19.6%
5,591 $883,000
Q1 2024

May 14, 2024

BUY
$93.7 - $141.53 $616,733 - $931,550
6,582 Added 1769.35%
6,954 $900,000
Q4 2023

Feb 13, 2024

BUY
$67.31 - $124.76 $3,028 - $5,614
45 Added 13.76%
372 $35,000
Q2 2023

Aug 14, 2023

SELL
$106.4 - $157.19 $851 - $1,257
-8 Reduced 2.39%
327 $37,000
Q1 2023

May 12, 2023

SELL
$117.53 - $155.99 $1,292 - $1,715
-11 Reduced 3.18%
335 $46,000
Q4 2022

Feb 14, 2023

BUY
$100.86 - $132.13 $34,897 - $45,716
346 New
346 $44,000
Q1 2021

Apr 26, 2021

SELL
$72.25 - $168.95 $90,312 - $211,187
-1,250 Closed
0 $0
Q4 2020

Jan 27, 2021

BUY
$125.56 - $178.74 $156,950 - $223,425
1,250 New
1,250 $213,000
Q3 2020

Nov 03, 2020

SELL
$127.12 - $172.34 $196,019 - $265,748
-1,542 Closed
0 $0
Q2 2020

Jul 29, 2020

BUY
$93.0 - $171.7 $143,406 - $264,761
1,542 New
1,542 $247,000
Q4 2018

Jan 29, 2019

SELL
$97.32 - $148.76 $133,231 - $203,652
-1,369 Closed
0 $0
Q3 2018

Oct 29, 2018

BUY
$115.31 - $161.51 $157,859 - $221,107
1,369 New
1,369 $221,000

Others Institutions Holding SRPT

About Sarepta Therapeutics, Inc.


  • Ticker SRPT
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 87,567,904
  • Market Cap $9.97B
  • Description
  • Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mut...
More about SRPT
Track This Portfolio

Track New Edge Advisors, LLC Portfolio

Follow New Edge Advisors, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of New Edge Advisors, LLC, based on Form 13F filings with the SEC.

News

Stay updated on New Edge Advisors, LLC with notifications on news.